Pierre Fabre S.a.

Pierre Fabre Medicament

P. F. Medicament

Gerard Normier

Anne-Marie Pinel

Lucien Dussourd d'Hinterland

Jacques Durand

Lucien D D'Hinterland

Alain Le Pape

Hans Binz

Hubert Serre

Michel Favaron

Lucien Dussourdd'Hinterland

Lucien Pradayrol

Souhail Delassan

The present invention relates to a D 25 polysaccharide compound whose lipid has been partially removed and to its derivatives, wherein at least 85% by weight, preferably 90% of the compound, exists in aqueous solution in monomeric form. The 30 kD molecular weight polysaccharide compound extracted from the membrane proteoglycan of the bacterium Klebsiella pneumoniae is mentioned in particular. The amount of palmitic fatty acids which is bound to it in esterified form does not exceed 0.01% by weight of the compound and the amount of palmitic fatty acids which is associated with it in the free form does not exceed 0.1% by weight of the compound.

Partially delipidated D25 polysaccaride composition for imaging and

The present invention relates to an aerosol composition containing a carrier agent capable of recognizing and binding to inflammatory and tumor foci mobilizing macrophages in their immediate environment, and an aerosol substrate, characterized in that the said carrier agent consists of a polysaccharide compound selected from the compound D 25, extracted from the membrane proteoglycans of the bacterium Klebsiella pneumoniae and having a molecular weight of 30.+-.0.10 Kd, and the compound oxidized D 25 in which the galactofuranoser residue (Gal.sub.f) of the linear polysaccharide chain of D 25 has been converted to arabinose, and their amide, ester or ether type derivatives, as well as their quaternary ammonium derivatives and salts, and also the derivatives obtained by grafting of phosphatides.

Method for detecting and locating inflammatory or tumor foci in a

The present invention relates to a polysaccharide derivative, which is a derivative of D.25 in which the galactofuranose (Gal.sub.f) residues of the linear polysaccharide chain have been converted at least partly to arabinose. It also relates to the process for its preparation, to its use as an immunostimulant, and to pharmaceutical compositions containing the derivative.

Derivative of D.25, process for its preparation, its use as an

The invention relates to a polysaccharide derivative which is an amide, an ester, an ether, a salt or a quaternary ammonium derivative of D.25 with an amine, an acid or an alcohol.

Immunomodulators obtained semisynthetically from a bacterial

The present invention relates to a membrane polysaccharide of bacterial origin having the following quantitative analytical composition:

Membrane polysaccharides which are useful as immunostimulants

The present invention relates to a method of preparing bacterial membranous proteoglycans with an action which induces interferon from soluble membranous proteoglycans of a strain of gram-negative bacterium, wherein the soluble membranous proteoglycans of a strain of gram-negative bacterium are hydrolyzed by lysozyme and the proteoglycans with a molecular weight between 200,000 and 400,000 are separated from the hydrolysis product. The products obtained are useful as a medicament.

Method of preparing immunostimulant proteoglycans which induce

The present invention relates to a vaccinal complex containing a specific antigen. This is a vaccinal complex characterized in that it is composed of bacterial ribosomal RNA or fragments of bacterial ribosomal RNA on which are coupled from 1 to 5% by weight of a specific antigen of bacterial serotype. This complex may be used as a vaccine.

Vaccinal complex containing a specific antigen and vaccine containing it

This invention relates to a process for the preparation of purified bacterial membranal proteoglycans. The process comprises at least one step in which crude proteoglycans are treated in aqueous medium with a base or a hypobromite, followed by elimination of the excess reactant and the insoluble residue, the purified proteoglycans being present in aqueous solution. The thus obtained purified proteoglycans may be used as immunity adjuvants in vaccines without causing side-effects such as pyrogenic reactions.

Preparations of purified bacterial membranal proteoglycans

Immunostimulating preparations based on ribosomal RNA's and a process

Vaccines which comprise in association the ribosomal fraction extracted from the bacterias against which a protection is wanted, and the peptidoglycanes extracted from the membranes of at least one of the bacteria previously used.

Process for preparing vaccines based on antigenic ribosomal fractions

The present invention relates to an improved process for the preparation of plasminogen activator. This is a process for separating a plasminogen activator according to U.S. Pat. No. 3,998,947 characterized in that it comprises at least the following stages:

Process for obtaining a plasminogen activator

Process for the preparation of purified bacterial membranal proteoglycans

The present invention relates to a pharmaceutical composition comprising a plasminogen activator and a polysaccharide sulphate. The invention also covers a process for preparing the pharmaceutical composition and a process for preparing the plasminogen activator. The pharmaceutical compositions are useful in the treatment of circulatory disorders such as venous thromboses.

Growing community of inventors

Castres, France

Gerard Normier